Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A major phase 3 trial confirms that nivolumab plus ipilimumab dramatically extends survival in patients with MSI-H/dMMR metastatic colorectal cancer compared to chemotherapy. At five years, 77% of patients on the combo were still alive versus just 46% on chemo. Researchers say this cements the dual immunotherapy as a global first-line standard of care.
The final overall survival (OS) results from the phase 3 CheckMate 8HW trial are in, and they make a compelling case for immunotherapy over chemotherapy in a specific subset of colorectal cancer patients. Presented at ESMO Congress 2026 and simultaneously published in Annals of Oncology, the data show that nivolumab plus ipilimumab significantly outperforms both chemotherapy and nivolumab alone in patients with MSI-H or mismatch repair-deficient (dMMR) unresectable or metastatic colorectal cancer (CRC).
With a median follow-up of over five years, the combo's survival advantage was substantial — and the safety profile remained more manageable compared to chemotherapy, with far fewer treatment-related discontinuations.
By the Numbers
Why it matters: For the roughly 15% of metastatic CRC patients with MSI-H/dMMR tumors, this data solidifies nivolumab plus ipilimumab as the go-to first-line treatment — offering a meaningful shot at long-term survival that chemotherapy cannot match.
